TCRX
TScan Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
TScan Therapeutics, Inc.
0.18
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Lynx1 Capital ManagementLynx1 | $7.9M | 22.38% | 0.00% | |
| 2 | BVFBVF | $5.5M | 15.53% | 0.00% | |
| 3 | Baker Bros. AdvisorsBaker Bros. | $2.7M | 7.77% | 0.00% | |
| 4 | Vanguard Capital ManagementVanguardindex-like | $2.1M | 6.02% | +0.21% | |
| 5 | Two Sigma InvestmentsTwo Sigma | $1.9M | 5.44% | +61.26% | |
| 6 | Renaissance TechnologiesRenaissance Technologies | $1.3M | 3.70% | −2.78% | |
| 7 | Acadian Asset ManagementAcadian | $1.3M | 3.64% | +546.50% | |
| 8 | Deer ManagementDeer | $1.2M | 3.48% | 0.00% | |
| 9 | Millennium ManagementMillennium | $1.1M | 3.25% | −20.32% | |
| 10 | Jacobs Levy Equity ManagementJacobs Levy Equity | $1.0M | 2.93% | +29.87% | |
| 11 | Citadel AdvisorsCitadel | $989,026 | 2.82% | +216.92% | |
| 12 | BlackRockBlackRockindex-like | $974,860 | 2.78% | −45.97% | |
| 13 | Boothbay Fund ManagementBoothbay Fund | $756,873 | 2.15% | new | |
| 14 | Marshall WaceMarshall Wace | $673,616 | 1.92% | +189.60% | |
| 15 | DC FundsDC Funds | $617,463 | 1.76% | 0.00% | |
| 16 | Geode Capital ManagementGeodeindex-like | $573,401 | 1.63% | −5.21% | |
| 17 | D. E. ShawD. E. Shaw | $537,489 | 1.53% | +71.60% | |
| 18 | GSA Capital PartnersGSA Capital Partners | $537,000 | 1.53% | +44.63% | |
| 19 | Kalehua Capital ManagementKalehua | $445,824 | 1.27% | new | |
| 20 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $356,675 | 1.02% | +19.03% | |
| 21 | Jane Street GroupJane Street | $236,687 | 0.67% | +67.21% | |
| 22 | Verdad AdvisersVerdad | $228,127 | 0.65% | +73.70% | |
| 23 | State StreetState Streetindex-like | $203,187 | 0.58% | 0.00% | |
| 24 | Mizuho Securities USAMizuho Securities USA | $201,509 | 0.57% | new | |
| 25 | Morgan StanleyMorgan Stanley | $193,952 | 0.55% | +13.96% |
59 managers report $35.1M of TScan Therapeutics on form 13F for the quarter ended Jun 30 '26. 13 of them hold 80% of it; Lynx1 is largest at 22.38%.
Linked news
Expected move
No implied move.
No implied move.
No implied move.